Search results
Fulcrum Therapeutics Inc (FULC) Reports Q3 2023 Financial Results and Business Highlights
GuruFocus.com via Yahoo Finance· 7 months agoFulcrum Therapeutics Inc (NASDAQ:FULC) reported a net loss of $24.0 million for Q3 2023, compared to...
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Q4 2023 Earnings Call Transcript
Insider Monkey via Yahoo Finance· 3 months agoFulcrum Therapeutics, Inc. (NASDAQ:FULC) Q4 2023 Earnings Call Transcript February 27, 2024 Fulcrum...
Investors in Fulcrum Therapeutics (NASDAQ:FULC) have unfortunately lost 45% over the last year
Simply Wall St. via Yahoo Finance· 9 months agoFulcrum Therapeutics, Inc. (NASDAQ:FULC) shareholders should be happy to see the share price up 18%...
Further weakness as Fulcrum Therapeutics (NASDAQ:FULC) drops 10% this week, taking one-year losses...
Simply Wall St. via Yahoo Finance· 2 years agoIt is doubtless a positive to see that the Fulcrum Therapeutics, Inc. (NASDAQ:FULC) share price has...
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) institutional owners may be pleased with recent gains after...
Simply Wall St. via Yahoo Finance· 3 months agoKey Insights Significantly high institutional ownership implies Fulcrum Therapeutics' stock price is...
Will Fulcrum Therapeutics (NASDAQ:FULC) Spend Its Cash Wisely?
Simply Wall St. via Yahoo Finance· 2 weeks agoThere's no doubt that money can be made by owning shares of unprofitable businesses. For example,...
Fulcrum Therapeutics Full Year 2023 Earnings: Beats Expectations
Simply Wall St. via Yahoo Finance· 3 months agoFulcrum Therapeutics (NASDAQ:FULC) Full Year 2023 Results Key Financial Results Net loss: US$97.3m...
Time To Worry? Analysts Just Downgraded Their Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Outlook
Simply Wall St. via Yahoo Finance· 2 years agoToday is shaping up negative for Fulcrum Therapeutics, Inc. (NASDAQ:FULC) shareholders, with the...
FDA Slams Break On Fulcrum Therapeutics' Sickle Cell Disease Study, Shares Plummet
Benzinga via Yahoo Finance· 1 year agoThe FDA verbally informed Fulcrum Therapeutics Inc (NASDAQ: FULC) that it has issued a full clinical...
Here's Why We're Watching Fulcrum Therapeutics' (NASDAQ:FULC) Cash Burn Situation
Simply Wall St. via Yahoo Finance· 7 months agoThere's no doubt that money can be made by owning shares of unprofitable businesses. For example,...